Allogene Therapeutics ALLO

$ 2.19 4.03%

Quarterly report 2024-Q3
added 11-07-2024

Allogene Therapeutics Balance Sheet 2011-2024 | ALLO

Annual Balance Sheet Allogene Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	12 M	39.2 M	-100 M	-139 M	-124 M	-58 M	-	-	-	-	-	-	-
Long Term Debt	88.3 M	95.1 M	69.9 M	50.8 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	6.78 M	6 M	3.2 M	2.97 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	55.7 M	41.2 M	-	-	-	-	-	-	-
Total Current Liabilities	37.1 M	53.7 M	47.9 M	94.3 M	33.1 M	29.5 M	-	-	-	-	-	-	-
Total Liabilities	131 M	155 M	126 M	148 M	88.8 M	70.7 M	2 K	-	-	-	-	-	-
Deferred Revenue	86 K	95 K	156 K	39 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.56 B	-1.23 B	-895 M	-713 M	-396 M	-212 M	-23 K	-	-	-	-	-	-
Total Assets	643 M	822 M	1.05 B	1.23 B	718 M	774 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	83.2 M	61.9 M	173 M	193 M	175 M	92.4 M	-	-	-	-	-	-	-
Book Value	512 M	667 M	925 M	1.08 B	629 M	703 M	-2 K	-	-	-	-	-	-
Total Shareholders Equity	512 M	667 M	925 M	1.01 B	629 M	703 M	-2 K	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Allogene Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	85.1 M	87 M	88.9 M	88.3 M	90.1 M	91.8 M	93.5 M	95.1 M	96.7 M	98.2 M	69 M	69.9 M	50.6 M	51.2 M	51.6 M	50.8 M	50.8 M	50.8 M	50.8 M	51.3 M	51.3 M	51.3 M	51.3 M	34.5 M	34.5 M	34.5 M	34.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	125 M	132 M	125 M	131 M	129 M	148 M	155 M	151 M	148 M	146 M	109 M	122 M	109 M	103 M	109 M	148 M	148 M	148 M	148 M	88.8 M	88.8 M	88.8 M	88.8 M	70.7 M	70.7 M	70.7 M	70.7 M	2 K	2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	86 K	86 K	236 K	229 K	273 K	885 K	889 K	836 K	406 K	423 K	365 K	305 K	239 K	39 M	39 M	39 M	39 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.76 B	-1.69 B	-1.63 B	-1.56 B	-1.47 B	-1.41 B	-1.33 B	-1.24 B	-1.14 B	-1.06 B	-983 M	-903 M	-828 M	-750 M	-679 M	-646 M	-646 M	-646 M	-646 M	-396 M	-396 M	-396 M	-396 M	-212 M	-212 M	-212 M	-212 M	-23 K	-23 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	589 M	647 M	586 M	643 M	712 M	771 M	747 M	817 M	888 M	948 M	965 M	1.04 B	1.08 B	1.13 B	1.18 B	1.23 B	1.23 B	1.23 B	1.23 B	718 M	718 M	718 M	718 M	774 M	774 M	774 M	774 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	51.2 M	171 M	51 M	83.2 M	79.5 M	165 M	120 M	61.9 M	84.6 M	106 M	94.8 M	173 M	199 M	233 M	237 M	193 M	183 M	183 M	183 M	175 M	175 M	175 M	175 M	92.4 M	92.4 M	92.4 M	92.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	464 M	515 M	461 M	512 M	583 M	623 M	592 M	666 M	740 M	802 M	855 M	916 M	970 M	1.02 B	1.07 B	1.08 B	1.08 B	1.08 B	1.08 B	629 M	629 M	629 M	629 M	703 M	703 M	703 M	703 M	-2 K	-2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	464 M	515 M	461 M	512 M	581 M	621 M	592 M	666 M	740 M	802 M	855 M	916 M	970 M	1.02 B	1.07 B	1.08 B	1.08 B	1.08 B	1.08 B	629 M	629 M	629 M	629 M	703 M	703 M	703 M	703 M	-2 K	-2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency